Herbert Smith Freehills advises sole sponsor on Rainmed Medical Limited's Hong Kong IPO 史密夫斐尔律师事务所作为独家保荐人律师为润迈德医疗香港上市提供法律服务

Leading international law firm Herbert Smith Freehills has advised Huatai Financial Holdings as the sole sponsor of medical device company Rainmed Medical Limited (02297.HK)’s mainboard listing on the Stock Exchange of Hong Kong.

Rainmed Medical listed on 8 July 2022. The company designs, develops and commercialises vascular interventional surgical robots for coronary angiography treatment.

"We are delighted to have worked with Rainmed Medical, one of the leading medical device specialists in this critical area, on its successful listing on the Hong Kong Stock Exchange,” said Hong Kong partner Matt Emsley. "We congratulate the company and the sole sponsor on this successful IPO."

Herbert Smith Freehills has advised on a number of biotech listings since the Hong Kong stock exchange introduced its new regime for biotech listings in 2018, including those of Lepu Biopharma (02157.HK), Shanghai Bio-heart (02185.HK), Abbisko Cayman Limited (02256.HK), Acotec Scientific Holdings Limited (06669.HK), Shanghai HeartCare Medical Technology (06609.HK), Brii Biosciences (02137.HK), CARsgen Therapeutics (02171.HK), Antengene Corporation Limited (06996.HK), Peijia Medical (09996.HK), SinoMab BioScience Limited (03681.HK), TOT BIOPHARM (01875.HK) and Shanghai Junshi Biosciences (01877.HK).

"We have advised a huge number of Chinese companies seeking listings in Hong Kong, and we look forward to continuing to support issuers and sponsors on their fundraising activities," said Herbert Smith Freehills Kewei joint operation partner Stanley Xie.

"Our team have collaborated closely to provide seamless service, combining efforts from our offices in Hong Kong and Chinese mainland," said Hong Kong senior registered foreign lawyer Jin Kong. "It is rewarding to see the success of the company and the sponsor.”

Partners Matt, Stanley and Jin Kong jointly led the team advising the sole sponsor, assisted by counsel Agatha Shen, associates Sean Ji, Crystal Chan, Kaiwen Sun, Sean Gao and Wang Ting. Senior associate Echo Shen, trainee solicitor Colbert Hung and legal assistants Jessica Lu, Phyllis Liang, Tiffany Chan, Han Ye and Katherine Chen also provided support. 

Legal manager Marine Jin led Herbert Smith Freehills Kewei Joint Operation’s Alternative Legal Services business to provide high-efficiency solutions for verification and other document-intensive processes during the listing, assisted by senior legal analysts Shawna Peng and Jean Zhou, and legal analysts Huaqian Zhang and Chunqin Li.

全球领先的律师事务所史密夫斐尔于医疗器械公司润迈德医疗（02297.HK）在香港联交所主板上市的项目中担任独家保荐人华泰金融控股的律师并提供法律服务。

润迈德医疗的股份于2022年7月8日开始在香港联交所交易。该公司专注于基于冠状脉造影的血管介入手术机器人的设计、开发和商业化。

史密夫斐尔香港办公室合伙人艾迈修（Matt Emsley）表示：“润迈德医疗是医疗器械这一关键领域领先的公司之一，我们非常荣幸为其在联交所上市提供助力。我们衷心向润迈德医疗和独家保荐人表示祝贺。” 

史密夫斐尔已经为众多生物科技公司在香港上市提供法律服务，包括乐普生物（02157.HK）、百心安（02185.HK）、和誉开曼（02256.HK）、先瑞达医疗（06669.HK）、心玮医疗（06609.HK）、腾盛博药（02137.HK）、科济药业（02171.HK）、德琪医药（06996.HK）、沛嘉医疗（09996.HK）、中国抗体（03681.HK）、东曜药业（01875.HK）和君实生物（01877.HK）。

科伟史密夫斐尔联营办公室合伙人谢守德（Stanley Xie）表示：“我们已经为大量中国公司在香港上市提供咨询，期待继续为发行人和保荐人就融资活动提供支持。”

史密夫斐尔香港办公室合伙人（高级注册外国律师）孔瑾（Jin Kong）表示：“我们的团队密切配合，在中国香港和内地办公室的同事们协同努力，为客户提供无缝服务。见证公司和保荐人的成功令人倍感欣慰。”

合伙人艾迈修、谢守德和孔瑾率领律师团队为此次上市的独家保荐人提供法律服务。主要团队成员包括资深顾问沈雪琦、季晓源（Associate）、陈念彤（Associate）、孙凯文（Associate）、高炜华（Associate）和王婷（Associate）。沈黄贇（Senior Associate）、洪从译（Trainee Solicitor）、卢嘉铮（Legal Assistant）、梁小雨（Legal Assistant）、陈可宜 （Legal Assistant）、叶晗（Legal Assistant）和陈旖珏（Legal Assistant）也提供了支持。

金燊（Legal Manager）率领的科伟史密夫斐尔联营办公室替代性法律服务（ALT）联合团队在上市项目期间为招股书验证及其他文件密集型工作提供高效率的解决方案。彭祺程（Senior Legal Analyst）、周雅菁 （Senior Legal Analyst）、 张华倩（Legal Analyst）和李纯沁（Legal Analyst）提供支持。